ADAPTIVE BIOTECHNOLOGIES CORPORATION Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer of $12.95 million as of 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger · last filed 2025-11-05
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $12.95M.
- 2023-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $19.96M.
- 2023-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $67.99M.
- 2023-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $142.37M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer |
|---|---|
| 2025-09-30 | $12.95M 10-Q · filed 2025-11-05 |
| 2023-09-30 | $19.96M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $67.99M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $142.37M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $213.50M 10-K · filed 2023-02-14 |
| 2022-09-30 | $118.95K 10-Q · filed 2022-11-03 |
| 2019-06-30 | $5.00M 10-Q · filed 2019-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |